Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9004410 | 0.98 | HPGD (0.50) | HPGDMIFKLK7MAPTMEN1 | |
| SCHEMBL19452478 | 0.84 | HPGD (0.48) | HPGDMIFKLK7MAPTMEN1 | |
| SCHEMBL11843186 | 0.84 | HPGD (0.48) | HPGDMIFKLK7MAPTMEN1 | |
| SCHEMBL10559579 | 0.84 | EPHX1 (0.42) | HPGDMIFLMNASMN1; SMN2 | |
| SCHEMBL9011955 | 0.83 | NAAA (0.55) | HPGDMIFKLK7MAPTMEN1 | |
| SCHEMBL10623651 | 0.82 | HPGD (0.52) | HPGDMIFKLK7MAPTMEN1 | |
| SCHEMBL10557471 | 0.82 | HPGD (0.52) | HPGDMIFKLK7MAPTMEN1 | |
| SCHEMBL25252093 | 0.81 | NAAA (0.56) | HPGDMIFKLK7MAPTMEN1 | |
| SCHEMBL9012245 | 0.81 | NAAA (0.56) | HPGDMIFKLK7MAPTMEN1 | |
| SCHEMBL697221 | 0.80 | ALDH1A1 (0.50) | HPGDKLK7MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1265911-A2 | 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS ANTIPROGESTATIONAL AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001074840-A2 | 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNA 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS ANTIPROGESTATIONAL AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES (US) | 2001-10-11 | — | — | WO | disclosed |